Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(6):819–823. doi: 10.1054/bjoc.2000.1673

Lectin binding to cutaneous malignant melanoma: HPA is associated with metastasis formation

A Thies 1, I Moll 2, J Berger 3, U Schumacher 1
PMCID: PMC2363810  PMID: 11259098

Abstract

Changes in protein glycosylation of tumour cells, as detected by lectin histochemistry, have been associated with metastasis formation in several human malignancies. This study analysed the association between lectin binding and metastasis in cutaneous malignant melanoma. In a 10-year retrospective study, sections of 100 primary cutaneous malignant melanomas were histochemically stained for the following 5 lectins: HPA, SNA-I, MAA, WGA and PHA-L, differing in their carbohydrate specificity. Since differences in the results of HPA binding depending on methodology have been reported, an indirect and a biotinylated method were employed for HPA. Kaplan–Meier analysis of time to first metastasis revealed a positive correlation between HPA binding and metastasis for both methods, with the biotinylated HPA method (P< 0.0001) being superior to the ‘indirect’ method (P = 0.0006). Cox regression analysis demonstrated that even after adjustment for stage, HPA positivity is an independent predictor for metastasis. The results of the present study indicate that N -acetyl-galactosamine/-glucosamine residues, recognized by HPA, are linked to metastasis in malignant melanoma. In contrast, β1-6 branched oligosaccharides or sialic acid residues, both of which were correlated with metastasis in other malignancies, are of no functional importance for metastasis formation in malignant melanoma. Thus, HPA proved to be a useful and independent prognostic marker for the metastatic phenotype of melanoma. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: melanoma, lectins, metastasis, prognosis, HPA

Full Text

The Full Text of this article is available as a PDF (118.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brooks S. A., Lymboura M., Schumacher U., Leathem A. J. Histochemistry to detect Helix pomatia lectin binding in breast cancer: methodology makes a difference. J Histochem Cytochem. 1996 May;44(5):519–524. doi: 10.1177/44.5.8627008. [DOI] [PubMed] [Google Scholar]
  2. Cochran A. J., Wen D. R., Berthier-Vergnes O., Bailly C., Doré J. F., Bérard F., Moulin G., Thomas L. Cytoplasmic accumulation of peanut agglutinin-binding glycoconjugates in the cells of primary melanoma correlates with clinical outcome. Hum Pathol. 1999 May;30(5):556–561. doi: 10.1016/s0046-8177(99)90201-0. [DOI] [PubMed] [Google Scholar]
  3. Fenlon S., Ellis I. O., Bell J., Todd J. H., Elston C. W., Blamey R. W. Helix pomatia and Ulex europeus lectin binding in human breast carcinoma. J Pathol. 1987 Jul;152(3):169–176. doi: 10.1002/path.1711520305. [DOI] [PubMed] [Google Scholar]
  4. Fernandes B., Sagman U., Auger M., Demetrio M., Dennis J. W. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 1991 Jan 15;51(2):718–723. [PubMed] [Google Scholar]
  5. Hart I. R., Goode N. T., Wilson R. E. Molecular aspects of the metastatic cascade. Biochim Biophys Acta. 1989 Jul 28;989(1):65–84. doi: 10.1016/0304-419x(89)90035-8. [DOI] [PubMed] [Google Scholar]
  6. Hart I. R., Saini A. Biology of tumour metastasis. Lancet. 1992 Jun 13;339(8807):1453–1457. doi: 10.1016/0140-6736(92)92039-i. [DOI] [PubMed] [Google Scholar]
  7. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  8. Ikeda Y., Mori M., Adachi Y., Matsushima T., Sugimachi K. Prognostic value of the histochemical expression of helix pomatia agglutinin in advanced colorectal cancer. A univariate and multivariate analysis. Dis Colon Rectum. 1994 Feb;37(2):181–184. doi: 10.1007/BF02047545. [DOI] [PubMed] [Google Scholar]
  9. Kakeji Y., Tsujitani S., Mori M., Maehara Y., Sugimachi K. Helix pomatia agglutinin binding activity is a predictor of survival time for patients with gastric carcinoma. Cancer. 1991 Dec 1;68(11):2438–2442. doi: 10.1002/1097-0142(19911201)68:11<2438::aid-cncr2820681119>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  10. Kjønniksen I., Rye P. D., Fodstad O. Helix pomatia agglutinin binding in human tumour cell lines: correlation with pulmonary metastases in nude mice. Br J Cancer. 1994 Jun;69(6):1021–1024. doi: 10.1038/bjc.1994.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Leathem A. J., Brooks S. A. Predictive value of lectin binding on breast-cancer recurrence and survival. Lancet. 1987 May 9;1(8541):1054–1056. doi: 10.1016/s0140-6736(87)90482-x. [DOI] [PubMed] [Google Scholar]
  12. Leathem A., Dokal I., Atkins N. Lectin binding to normal and malignant breast tissue. Diagn Histopathol. 1983 Jul-Dec;6(3-4):171–180. [PubMed] [Google Scholar]
  13. Marks R., Kopf A. W. Cancer of the skin in the next century. Int J Dermatol. 1995 Jul;34(7):445–447. doi: 10.1111/j.1365-4362.1995.tb00605.x. [DOI] [PubMed] [Google Scholar]
  14. Mitchell B. S., Schumacher U. The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Histol Histopathol. 1999 Jan;14(1):217–226. doi: 10.14670/HH-14.217. [DOI] [PubMed] [Google Scholar]
  15. Orfanos C. E., Jung E. G., Rassner G., Wolff H. H., Garbe C. Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Stand 1993/94. Hautarzt. 1994 May;45(5):285–291. doi: 10.1007/s001050050071. [DOI] [PubMed] [Google Scholar]
  16. Prediction of lymph node involvement in breast cancer. Lancet. 1991 Aug 10;338(8763):392–393. [PubMed] [Google Scholar]
  17. Schumacher U., Adam E., Brooks S. A., Leathem A. J. Lectin-binding properties of human breast cancer cell lines and human milk with particular reference to Helix pomatia agglutinin. J Histochem Cytochem. 1995 Mar;43(3):275–281. doi: 10.1177/43.3.7868857. [DOI] [PubMed] [Google Scholar]
  18. Schumacher U., Higgs D., Loizidou M., Pickering R., Leathem A., Taylor I. Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma. Cancer. 1994 Dec 15;74(12):3104–3107. doi: 10.1002/1097-0142(19941215)74:12<3104::aid-cncr2820741207>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  19. Shiraishi T., Atsumi S., Yatani R. Comparative study of prostatic carcinoma bone metastasis among Japanese in Japan and Japanese Americans and whites in Hawaii. Adv Exp Med Biol. 1992;324:7–16. doi: 10.1007/978-1-4615-3398-6_2. [DOI] [PubMed] [Google Scholar]
  20. Tao T. W., Burger M. M. Lectin-resistant variants of mouse melanoma cells. I. Altered metastasizing capacity and tumorigenicity. Int J Cancer. 1982 Apr 15;29(4):425–430. doi: 10.1002/ijc.2910290411. [DOI] [PubMed] [Google Scholar]
  21. Walker R. A. Helix pomatia and prognosis of breast cancer. Br J Cancer. 1993 Sep;68(3):453–454. doi: 10.1038/bjc.1993.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Yoshida Y., Okamura T., Shirakusa T. An immunohistochemical study of helix pomatia agglutinin binding on carcinomas of the esophagus. Surg Gynecol Obstet. 1993 Sep;177(3):299–302. [PubMed] [Google Scholar]
  23. Zhang L., Zhou W., Velculescu V. E., Kern S. E., Hruban R. H., Hamilton S. R., Vogelstein B., Kinzler K. W. Gene expression profiles in normal and cancer cells. Science. 1997 May 23;276(5316):1268–1272. doi: 10.1126/science.276.5316.1268. [DOI] [PubMed] [Google Scholar]
  24. van den Oord J. J., Maes A., Stas M., Nuyts J., De Wever I., De Wolf-Peeters C. Prognostic significance of nm23 protein expression in malignant melanoma. An immunohistochemical study. Melanoma Res. 1997 Apr;7(2):121–128. doi: 10.1097/00008390-199704000-00006. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES